黄斑部病变治疗药的全球市场 (2022年～2031年):适应症 (湿性老年性黄斑部病变·干性老年性黄斑部病变·其他) 别产业分析·规模·占有率·成长·趋势·预测

本报告提供全球黄斑部病变治疗药的市场调查，彙整市场概要，市场成长的各种影响因素分析，法规情景，开发平台分析，市场规模的转变·预测，各种区分·地区/各主要国家的明细，竞争环境，主要企业简介等资讯。

目录

第1章 序文

第2章 前提·调查手法

第3章 摘要整理:全球黄斑部病变治疗药市场

第4章 市场概要

• 概要
• 市场动态
  • 促进因素
  • 阻碍因素
  • 机会
• 全球黄斑部病变治疗药市场分析·预测

第5章 主要洞察

• 法规情景
• 开发平台分析
• 主要国家的疾病盛行率·发生率
• COVID-19:影响分析

第6章 全球黄斑部病变治疗药市场分析·预测:各适应症

• 简介·定义
• 主要调查结果·展开
• 市场预测
  • 湿性老年性黄斑部病变
  • 干性老年性黄斑部病变
  • 其他
• 市场魅力

第7章 全球黄斑部病变治疗药市场分析·预测:各类药物

• 简介·定义
• 主要调查结果·展开
• 市场预测
  • 抗血管内皮层生长因子
  • 其他
• 市场魅力

第8章 全球黄斑部病变治疗药市场分析·预测:各流通管道

• 简介·定义
• 主要调查结果·展开
• 市场预测
  • 医院
  • 眼科诊所
  • 门诊病人手术中心
• 市场魅力

第9章 全球黄斑部病变治疗药市场分析·预测:各地区

• 主要调查结果
• 市场预测
  • 北美
  • 欧洲
  • 亚太地区
  • 南美
  • 中东·非洲
• 市场魅力

第10章 北美的黄斑部病变治疗药市场分析·预测

第11章 欧洲的黄斑部病变治疗药市场分析·预测

第12章 亚太地区的黄斑部病变治疗药市场分析·预测

第13章 南美的黄斑部病变治疗药市场分析·预测

第14章 中东·非洲的黄斑部病变治疗药市场分析·预测

第15章 竞争情形

• 主要企业的竞争矩阵
• 企业占有率分析
• 企业简介
  • Pfizer, Inc.
  • AbbVie, Inc.
  • F. Hoffmann-La Roche, Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • Novartis AG
  • Santen Pharmaceutical Co., Ltd.

The report provides revenue of the global macular degeneration treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global macular degeneration treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the macular degeneration treatment market.

The report delves into the competitive landscape of the global macular degeneration treatment market. Key players operating in the global macular degeneration treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global macular degeneration treatment market profiled in this report.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Macular Degeneration Treatment Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Macular Degeneration Treatment Market Analysis and Forecast, 2017-2031
  • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. Regulatory Scenario
• 5.2. Pipeline Analysis
• 5.3. Disease Prevalence & incidence rate with key countries
• 5.4. Covid-19 Impact Analysis

6. Global Macular Degeneration Treatment Market Analysis and Forecast, by Disease Indication

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast, by Disease Indication, 2017-2031
  • 6.3.1. Wet Age-related Macular Degeneration
  • 6.3.2. Dry Age-related Macular Degeneration
  • 6.3.3. Others
• 6.4. Market Attractiveness Analysis, by Disease Indication

7. Global Macular Degeneration Treatment Market Analysis and Forecast, by Drug Class

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast, by Drug Class, 2017-2031
  • 7.3.1. Anti-vascular Endothelial Growth Factor
  • 7.3.2. Others
• 7.4. Market Attractiveness Analysis, by Drug Class

8. Global Macular Degeneration Treatment Market Analysis and Forecast, by Distribution Channel

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 8.3.1. Hospitals
  • 8.3.2. Ophthalmology Clinics
  • 8.3.3. Ambulatory Surgical Centers
• 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Macular Degeneration Treatment Market Analysis and Forecast, by Region

• 9.1. Key Findings
• 9.2. Market Value Forecast, by Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness Analysis, by Region

10. North America Macular Degeneration Treatment Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast, by Disease Indication, 2017-2031
  • 10.2.1. Wet Age-related Macular Degeneration
  • 10.2.2. Dry Age-related Macular Degeneration
  • 10.2.3. Others
• 10.3. Market Value Forecast, by Drug Class, 2017-2031
  • 10.3.1. Anti-vascular Endothelial Growth Factor
  • 10.3.2. Others
• 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
  • 10.4.1. Hospitals
  • 10.4.2. Ophthalmology Clinics
  • 10.4.3. Ambulatory Surgical Centers
• 10.5. Market Value Forecast, by Country, 2017-2031
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Disease Indication
  • 10.6.2. By Drug Class
  • 10.6.3. By Distribution Channel
  • 10.6.4. By Country

11. Europe Macular Degeneration Treatment Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Disease Indication, 2017-2031
  • 11.2.1. Wet Age-related Macular Degeneration
  • 11.2.2. Dry Age-related Macular Degeneration
  • 11.2.3. Others
• 11.3. Market Value Forecast, by Drug Class, 2017-2031
  • 11.3.1. Anti-vascular Endothelial Growth Factor
  • 11.3.2. Others
• 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
  • 11.4.1. Hospitals
  • 11.4.2. Ophthalmology Clinics
  • 11.4.3. Ambulatory Surgical Centers
• 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.5.1. Germany
  • 11.5.2. U.K.
  • 11.5.3. France
  • 11.5.4. Italy
  • 11.5.5. Spain
  • 11.5.6. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Disease Indication
  • 11.6.2. By Drug Class
  • 11.6.3. By Distribution Channel
  • 11.6.4. By Country/Sub-region

12. Asia Pacific Macular Degeneration Treatment Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Disease Indication, 2017-2031
  • 12.2.1. Wet Age-related Macular Degeneration
  • 12.2.2. Dry Age-related Macular Degeneration
  • 12.2.3. Others
• 12.3. Market Value Forecast, by Drug Class, 2017-2031
  • 12.3.1. Anti-vascular Endothelial Growth Factor
  • 12.3.2. Others
• 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
  • 12.4.1. Hospitals
  • 12.4.2. Ophthalmology Clinics
  • 12.4.3. Ambulatory Surgical Centers
• 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.5.1. China
  • 12.5.2. India
  • 12.5.3. Japan
  • 12.5.4. Australia & New Zealand
  • 12.5.5. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Disease Indication
  • 12.6.2. By Drug Class
  • 12.6.3. By Distribution Channel
  • 12.6.4. By Country/Sub-region

13. Latin America Macular Degeneration Treatment Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Disease Indication, 2017-2031
  • 13.2.1. Wet Age-related Macular Degeneration
  • 13.2.2. Dry Age-related Macular Degeneration
  • 13.2.3. Others
• 13.3. Market Value Forecast, by Drug Class, 2017-2031
  • 13.3.1. Anti-vascular Endothelial Growth Factor
  • 13.3.2. Others
• 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
  • 13.4.1. Hospitals
  • 13.4.2. Ophthalmology Clinics
  • 13.4.3. Ambulatory Surgical Centers
• 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Disease Indication
  • 13.6.2. By Drug Class
  • 13.6.3. By Distribution Channel
  • 13.6.4. By Country/Sub-region

14. Middle East & Africa Macular Degeneration Treatment Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Disease Indication, 2017-2031
  • 14.2.1. Wet Age-related Macular Degeneration
  • 14.2.2. Dry Age-related Macular Degeneration
  • 14.2.3. Others
• 14.3. Market Value Forecast, by Drug Class, 2017-2031
  • 14.3.1. Anti-vascular Endothelial Growth Factor
  • 14.3.2. Others
• 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
  • 14.4.1. Hospitals
  • 14.4.2. Ophthalmology Clinics
  • 14.4.3. Ambulatory Surgical Centers
• 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 14.5.1. GCC
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Disease Indication
  • 14.6.2. By Drug Class
  • 14.6.3. By Distribution Channel
  • 14.6.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (by tier and size of companies)
• 15.2. Market Share Analysis, by Company, 2021
• 15.3. Company Profiles
  • 15.3.1. Pfizer, Inc.
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Product Portfolio
    • 15.3.1.3. SWOT Analysis
    • 15.3.1.4. Financial Overview
    • 15.3.1.5. Strategic Overview
  • 15.3.2. AbbVie, Inc.
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Product Portfolio
    • 15.3.2.3. SWOT Analysis
    • 15.3.2.4. Financial Overview
    • 15.3.2.5. Strategic Overview
  • 15.3.3. F. Hoffmann-La Roche, Ltd.
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Product Portfolio
    • 15.3.3.3. SWOT Analysis
    • 15.3.3.4. Financial Overview
    • 15.3.3.5. Strategic Overview
  • 15.3.4. Regeneron Pharmaceuticals, Inc.
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Product Portfolio
    • 15.3.4.3. SWOT Analysis
    • 15.3.4.4. Financial Overview
    • 15.3.4.5. Strategic Overview
  • 15.3.5. Bayer AG
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Product Portfolio
    • 15.3.5.3. SWOT Analysis
    • 15.3.5.4. Financial Overview
    • 15.3.5.5. Strategic Overview
  • 15.3.6. Novartis AG
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Product Portfolio
    • 15.3.6.3. SWOT Analysis
    • 15.3.6.4. Financial Overview
    • 15.3.6.5. Strategic Overview
  • 15.3.7. Santen Pharmaceutical Co., Ltd.
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Product Portfolio
    • 15.3.7.3. SWOT Analysis
    • 15.3.7.4. Financial Overview
    • 15.3.7.5. Strategic Overview

List of Tables

• Table 01: Global Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
• Table 02: Global Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
• Table 03: Global Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 04: Global Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
• Table 05: North America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
• Table 06: North America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
• Table 07: North America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 08: North America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
• Table 08: Europe Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
• Table 09: Europe Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
• Table 10: Europe Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 11: Europe Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 12: Asia Pacific Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
• Table 13: Asia Pacific Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
• Table 14: Asia Pacific Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 15: Asia Pacific Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 16: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
• Table 17: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
• Table 18: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 19: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 20: Middle East & Africa Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
• Table 21: Middle East & Africa Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
• Table 22: Middle East & Africa Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 23: Middle East & Africa Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

• Figure 01: Global Macular Degeneration Treatment Market Snapshot
• Figure 02: Global Macular Degeneration Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
• Figure 03: Global Macular Degeneration Treatment Market Value Share, by Disease Indication, 2021
• Figure 04: Global Macular Degeneration Treatment Market Value Share, by Drug Class, 2021
• Figure 05: Global Macular Degeneration Treatment Market Value Share, by Distribution Channel, 2021
• Figure 06: Global Macular Degeneration Treatment Market Value Share, by Region, 2021
• Figure 07: Global Macular Degeneration Treatment Market Value Share Analysis, by Disease Indication, 2021 and 2031
• Figure 08: Global Macular Degeneration Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Wet AMD, 2017-2031
• Figure 09: Global Macular Degeneration Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Dry AMD, 2017-2031
• Figure 10: Global Macular Degeneration Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Other Indications, 2017-2031
• Figure 11: Global Macular Degeneration Treatment Market Attractiveness Analysis, by Disease Indication, 2022-2031
• Figure 12: Global Macular Degeneration Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
• Figure 13: Global Macular Degeneration Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Anti-vascular Endothelial Growth Factor, 2017-2031
• Figure 14: Global Macular Degeneration Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Others, 2017-2031
• Figure 15: Global Macular Degeneration Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
• Figure 16: Global Macular Degeneration Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
• Figure 17: Global Macular Degeneration Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Hospitals, 2017-2031
• Figure 18: Global Macular Degeneration Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Ophthalmology Clinics, 2017-2031
• Figure 19: Global Macular Degeneration Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Ambulatory Surgical Centers, 2017-2031
• Figure 20: Global Macular Degeneration Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
• Figure 21: Macular Degeneration Treatment Market Value Share Analysis, by Region, 2017 and 2031
• Figure 22: Macular Degeneration Treatment Market Attractiveness Analysis by Region, 2022-2031
• Figure 23: North America Macular Degeneration Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
• Figure 24 North America Macular Degeneration Treatment Market Value Share Analysis, by Drug Class, 2017 and 2031
• Figure 25: North America Macular Degeneration Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
• Figure 26: North America Macular Degeneration Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
• Figure 27: North America Macular Degeneration Treatment Market Attractiveness Analysis, by Disease Indication, 2022-2031
• Figure 28: North America Macular Degeneration Treatment Market Value Share Analysis, by Distribution Channel, 2017-2031
• Figure 29: North America Macular Degeneration Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
• Figure 30: North America Macular Degeneration Treatment Market Value Share Analysis, by Country, 2017 and 2031
• Figure 31: North America Macular Degeneration Treatment Market Attractiveness Analysis, by Country, 2022-2031
• Figure 32: Europe Macular Degeneration Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
• Figure 33: Europe Macular Degeneration Treatment Market Value Share Analysis, by Drug Class, 2017 and 2031
• Figure 34: Europe Macular Degeneration Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
• Figure 35: Europe Macular Degeneration Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
• Figure 36: Europe Macular Degeneration Treatment Market Attractiveness Analysis, by Disease Indication, 2022-2031
• Figure 37: Europe Macular Degeneration Treatment Market Value Share Analysis, by Distribution Channel, 2021-2031
• Figure 38: Europe Macular Degeneration Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
• Figure 39: Europe Macular Degeneration Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
• Figure 40: Europe Macular Degeneration Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 41: Asia Pacific Macular Degeneration Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
• Figure 42: Asia Pacific Macular Degeneration Treatment Market Value Share Analysis, by Drug Class, 2017 and 2031
• Figure 43: Asia Pacific Macular Degeneration Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
• Figure 44: Asia Pacific Macular Degeneration Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
• Figure 45: Asia Pacific Macular Degeneration Treatment Market Attractiveness Analysis, by Disease Indication, 2022-2031
• Figure 46: Asia Pacific Macular Degeneration Treatment Market Value Share Analysis, by Distribution Channel, 2017-2031
• Figure 47: Asia Pacific Macular Degeneration Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
• Figure 48: Asia Pacific Macular Degeneration Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
• Figure 49: Asia Pacific Macular Degeneration Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 50: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
• Figure 51: Latin America Macular Degeneration Treatment Market Value Share Analysis, by Drug Class, 2017 and 2031
• Figure 52: Latin America Macular Degeneration Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
• Figure 53: Latin America Macular Degeneration Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
• Figure 54: Latin America Macular Degeneration Treatment Market Attractiveness Analysis, by Disease Indication, 2022-2031
• Figure 55: Latin America Macular Degeneration Treatment Market Value Share Analysis, by Distribution Channel, 2017-2031
• Figure 56: Latin America Macular Degeneration Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
• Figure 57: Latin America Macular Degeneration Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
• Figure 58: Latin America Macular Degeneration Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 59: Middle East & Africa Macular Degeneration Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
• Figure 60: Middle East & Africa Macular Degeneration Treatment Market Value Share Analysis, by Drug Class, 2017 and 2031
• Figure 61: Middle East & Africa Macular Degeneration Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
• Figure 62: Middle East & Africa Macular Degeneration Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
• Figure 63: Middle East & Africa Macular Degeneration Treatment Market Attractiveness Analysis, by Disease Indication, 2022-2031
• Figure 64: Middle East & Africa Macular Degeneration Treatment Market Value Share Analysis, by Distribution Channel, 2017-2031
• Figure 65: Middle East & Africa Macular Degeneration Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
• Figure 66: Middle East & Africa Macular Degeneration Treatment Market Value Share Analysis, by Country, 2017 and 2031
• Figure 67: Middle East & Africa Macular Degeneration Treatment Market Attractiveness Analysis, by Country, 2022-2031